Clinical practice recommendations from the American Diabetes association (ADA) indicate that treatment with antiplatelet agents should be adopted for patients with diabetes with evidence of macrovascular disease, and for adults with diabetes

INTRODUCTION and mortality seen in patients with type II diabetes mellitus is the result of microand macrovascular occlusive disease in which thrombosis plays an important part. Diabetic patients Diabetes mellitus (DM) is a metabolic syndrome characterized have lower anti thrombin III activity, protein C deficiency, by derangements in carbohydrate, protein and fat metabolism 1 increased kallikrein and increased levels of XII, XI, VIII and von associated with insulin deficiency or resistance. It is one of the 6 willebrand factor. most common chronic endocrine disorders contributing to 2 Increased platelet reactivity could be due to reduction in the morbidity and mortality worldwide.